First Human Surgery Performed with SINTX's FDA-Cleared SINAPTIC® Foot & Ankle Implant
SINT sits 49% above its 52-week low of $1.71 on light trading volume (0.4× avg).
Summary
Sintx Technologies announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. This milestone signifies the company's entry into the foot and ankle reconstruction market, a new and growing segment for its silicon nitride biomaterial platform. While the SINAPTIC system received FDA 510(k) clearance in October 2025, this first surgery represents a critical step in its commercialization strategy, validating real-world application. For a micro-cap company, this operational progress is material, indicating movement towards broader market adoption and potential revenue generation from this new product line. Investors will now monitor the commercial launch and adoption rates of the SINAPTIC system.
At the time of this announcement, SINT was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $1.71 to $6.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.